DE102008062136B4 - Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch - Google Patents

Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch Download PDF

Info

Publication number
DE102008062136B4
DE102008062136B4 DE102008062136A DE102008062136A DE102008062136B4 DE 102008062136 B4 DE102008062136 B4 DE 102008062136B4 DE 102008062136 A DE102008062136 A DE 102008062136A DE 102008062136 A DE102008062136 A DE 102008062136A DE 102008062136 B4 DE102008062136 B4 DE 102008062136B4
Authority
DE
Germany
Prior art keywords
lactophorin
dpp4
seq
peptides
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE102008062136A
Other languages
German (de)
English (en)
Other versions
DE102008062136A1 (de
Inventor
Karen Depta
Dr. Al Zoubi Khaled
Dr. Al Falah Marwan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KAMAMED GMBH, DE
Original Assignee
KAMAMED UG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KAMAMED UG filed Critical KAMAMED UG
Priority to DE102008062136A priority Critical patent/DE102008062136B4/de
Priority to PCT/EP2009/008768 priority patent/WO2010072327A2/de
Publication of DE102008062136A1 publication Critical patent/DE102008062136A1/de
Application granted granted Critical
Publication of DE102008062136B4 publication Critical patent/DE102008062136B4/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE102008062136A 2008-12-16 2008-12-16 Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch Active DE102008062136B4 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102008062136A DE102008062136B4 (de) 2008-12-16 2008-12-16 Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
PCT/EP2009/008768 WO2010072327A2 (de) 2008-12-16 2009-12-08 Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008062136A DE102008062136B4 (de) 2008-12-16 2008-12-16 Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch

Publications (2)

Publication Number Publication Date
DE102008062136A1 DE102008062136A1 (de) 2010-06-17
DE102008062136B4 true DE102008062136B4 (de) 2012-05-03

Family

ID=42168685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102008062136A Active DE102008062136B4 (de) 2008-12-16 2008-12-16 Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch

Country Status (2)

Country Link
DE (1) DE102008062136B4 (it)
WO (1) WO2010072327A2 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150018566A1 (en) 2011-08-25 2015-01-15 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Tubulin binding agents
JP5832049B2 (ja) * 2012-03-09 2015-12-16 森永乳業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
JP6517732B2 (ja) * 2016-06-01 2019-05-22 株式会社ニッピ Ｄｐｐ−４阻害剤、血糖値上昇抑制剤およびｄｐｐ−４阻害用食品
US10336817B2 (en) 2016-10-14 2019-07-02 Sultan Qaboos University Therapeutic composition of camel milk
CN109645123A (zh) * 2018-11-06 2019-04-19 新疆金驼投资股份有限公司 一种具有调节脂代谢功能的益生菌jt6骆驼乳粉组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004040452A1 (de) * 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
WO2006068840A1 (en) * 2004-12-16 2006-06-29 Bausch & Lomb Incorporated Dot radial ringed placido

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
PT1096951E (pt) * 1998-07-15 2003-01-31 Ursapharm Arzneimittel Gmbh Utilizacao de proteases de bromelaina para a preparacao de um medicamento para a inibicao de coagulacao do sangue
DE19834591A1 (de) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
GB9819137D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Component of bromelain
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1831361B1 (en) * 2004-12-23 2012-01-25 Campina Nederland Holding B.V. Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use
JP4915833B2 (ja) * 2005-07-01 2012-04-11 雪印メグミルク株式会社 ジペプチジルペプチダーゼｉｖ阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004040452A1 (de) * 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
WO2006068840A1 (en) * 2004-12-16 2006-06-29 Bausch & Lomb Incorporated Dot radial ringed placido

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CABA-Abstract 2005:76501 zu Konuspayeva G. [u.a.]: Lactoferrin of camel milk of Kazakhstan. In: Desertification combat and food safety: the added value of camel producers, Ashkabad, Turkmenistan, 19-21 April 2004, (2005) S.158-167 *
CABA-Abstract 2006:192424 zu Wernery,U.: Camel milk, the white gold the desert. In: Journal of Camel Practice and Research, 2006, Vol.13, No.1, S.15-26 *
CABA-Abstract 2008:257088 zu Shabo,Y. [u.a.]: Etiology of Crohn's disease and camel milk treatment. In: Journal of Camel Practice and Research, 2008, Vol.15, No.1, S.55-59 *
Kappeler S. [u.a.]: Alternative Splicing of Lactophorin mRNA from Lactating Mammary Gland of the Camel (Camelus dromedarius). In: J. Dairy Sci. 1999, Vol.82, S.2084-2093 *

Also Published As

Publication number Publication date
WO2010072327A3 (de) 2010-12-29
DE102008062136A1 (de) 2010-06-17
WO2010072327A2 (de) 2010-07-01

Similar Documents

Publication Publication Date Title
DE69732572T2 (de) Verwendung von glp-1 peptiden
EP0885961B1 (de) Neue Insulinderivate mit schnellem Wirkungseintritt
DE60012721T2 (de) Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
EP1398030B1 (de) Effektoren von Dipeptidylpeptidase IV
DE69737479T4 (de) Glp-1 derivate
EP2041169B1 (de) Amidiertes insulin glargin
DE69722397T2 (de) Insulin-derivate und ihre verwendung
DE69719798T2 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
DE69936446T2 (de) Inotropische und diuretische effekte von exendin und glp-1
DE60035987T2 (de) Metabolische intervention mit glp-1 oder seinen biologisch aktiven analogen zur verbesserung der funktion des ischämischen und wiederdurchbluteten gehirns
EP2229406B1 (de) Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE3326473A1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus
EP0140084B1 (de) Verfahren zur Herstellung von Insulin-Derivaten, deren B-Kette C-terminal verlängert ist, neue basisch modifizierte Insulin-Derivate, diese enthaltende Mittel und ihre Verwendung
DE10150203A1 (de) Peptidylketone als Inhibitoren der DPIV
DE102008003566A1 (de) Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2011003823A1 (de) Langsamwirkende insulinzubereitungen
EP2451437A2 (de) Wässrige insulinzubereitungen enthaltend methionin
EP2229407A2 (de) Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE10154689A1 (de) Substituierte Aminoketonverbindungen
DE102008062136B4 (de) Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
EP0427162B1 (de) Neue Insulinderivate, Verfahren zu deren Herstellung, ihre Verwendung und eine sie enthaltende pharmazeutische Zubereitung
DE69819488T2 (de) Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
DE3232034C2 (it)
CH650678A5 (de) Pharmazeutisches mittel aus human-insulin und human-proinsulin.

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
R016 Response to examination communication
R016 Response to examination communication
R018 Grant decision by examination section/examining division
R081 Change of applicant/patentee

Owner name: KAMAMED GMBH, DE

Free format text: FORMER OWNER: KAMAMED UG, 30539 HANNOVER, DE

Effective date: 20120628

R082 Change of representative

Representative=s name: PFENNING MEINIG & PARTNER GBR, DE

Effective date: 20120628

Representative=s name: PFENNING, MEINIG & PARTNER MBB PATENTANWAELTE, DE

Effective date: 20120628

R020 Patent grant now final

Effective date: 20120804